|
|
|
|
|
|
Sponsored by: |
Exelixis |
Information provided by: | Exelixis |
ClinicalTrials.gov Identifier: | NCT00526838 |
The purpose of this study is to assess the safety and tolerability of the multi-targeted protein kinase inhibitor XL228 (active against IGF1R, Src, FGFR, and BCR-Abl) administered as a weekly 1-hour intravenous infusion in subjects with advanced malignancies.
Condition | Intervention | Phase |
Cancer Lymphoma |
Drug: XL228 |
Phase I |
MedlinePlus related topics: | Cancer Lymphoma |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
Official Title: | A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL228 Administered Intravenously to Subjects With Advanced Malignancies |
Estimated Enrollment: | 63 |
Study Start Date: | September 2007 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |||||
UCLA Jonsson Comprehensive Cancer Center | Recruiting | ||||
Los Angeles, California, United States, 90095 | |||||
Contact: Lisa Yonemoto 310-825-4477 | |||||
Principal Investigator: Carolyn Britten, MD | |||||
United States, Michigan | |||||
University of Michigan Health System | Recruiting | ||||
Ann Arbor, Michigan, United States, 48109 | |||||
Contact: Nabeela Iqbal 734-232-0759 | |||||
Principal Investigator: David Smith, MD | |||||
United States, North Carolina | |||||
Duke University Medical Center | Recruiting | ||||
Durham, North Carolina, United States, 27710 | |||||
Contact: Sharon Norman 919-681-5257 | |||||
Principal Investigator: Herbert Hurwitz, MD |
Exelixis |
Study ID Numbers: | XL228-002 |
First Received: | September 6, 2007 |
Last Updated: | July 3, 2008 |
ClinicalTrials.gov Identifier: | NCT00526838 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|